THE-NAGA-GROUP-AG
5.10.2020 10:58:06 CEST | Business Wire | Press release
The NAGA GROUP (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for investing NAGA.com, posted another record quarter for 2020 with record sales of €7.1M (Q3 2019: €1.17M) and a strong EBITDA of €1.9M (Q3 2019: -€1.04M), based on preliminary figures. With close to 40,000 new accounts (Q3 2019: 7,100), the user base grew by 70% to the previous quarters, while the monthly trading volume in Q3 2020 jumped by 22 % well over 33 billion compared to Q2. (Q3 2019: €13 Billion) driven by a record no. of 1.6 million real-money transactions (Q3 2019: 947,000).
"We are happy with Q3. Especially in light of the seasonality and the lower client activity during summer, we once again have shown that our growth strategy pays off and is sustainable. Also, we have delivered a very solid EBITDA ratio despite increased expenses in growth. Given the growth in our active user base, we managed also to improve our platform experience and internal processes significantly to ensure further scalability. Looking at all our metrics it's clear by now that NAGA can grow even without the "COVID-effect", states Benjamin Bilski, CEO of NAGA.
The company also reports the launch of first-of-its-kind digital multi-webinars via the Streaming provider "Zoom". On 30th of September NAGA hosted the "Alpha-Event" which welcomed 1,500 students from 16 countries, mainly from the African and South-East-Asian region, who were connected simultaneously. The event was hosted by the world-renowned educator Andreas Thalassinos who joined NAGA recently. Given its success and the new in-house digital TV studio by NAGA, the "Alpha Trading Event" will be followed from now on by regular digital workshops and further events in the future to offer high-quality education for beginners in trading.
"Personally I am extremely proud of our new fully-digital educational concept. Given the times we are in, it is truly amazing to see over 1,000 people being all connected in real-time, interacting and learning about the financial markets together. These digital trainings are especially appreciated by our clients from South-East Asia and Africa. In fact, people all around the globe seek high-quality educational content which can be consumed from home and is presented in an interactive format. Together with our Director of Education Andreas Thalassinos we have set the benchmark for the next-generation financial market education. This will result in more global user growth to NAGA and empowers our vision to become not only a global community for investing, but also for an innovative provider of digital financial education", comments Benjamin Bilski. The video highlights of the "NAGA Alpha Webinar" can be found here: https://naga.com/alpha-trading-webinar
Additionally, NAGA announces the official release for its challenger Bank "NAGA PAY". On November 15th NAGA Pay will be available in the Google and Apple Appstore. The new payments startup by NAGA has received thousands of pre-registrations and will be a significant growth catalyst for NAGA's FinTech platform. The pre-registration is still available under naga.com/pay.
Given its strong growth in 2020, the launch of various initiatives and the prospects of opening the growth markets Australia and South-Africa while seeing very promising numbers from its China and South-East-Asian business, NAGA is well prepared for the current fourth quarter and eyes on 2021.
"The major rationale after Q1 was to enlarge our customer base, invest in our brand exposure and set up the company for scalability. We have a lot of promising initiatives in the pipeline such as the Australian and South-Africa market opening, we see a growing business in China and we have just welcomed over 50 new talents to our headquarters to support operational excellence throughout all departments. As mentioned in our Annual General Meeting last week: NAGA has its best cash-flow situation, highest average monthly volumes and the highest number of active users (as per September 2020) since inception. For the next quarters we need to invest into brand exposure, marketing and grow our team to offer a world-class trading experience by ensuring operational stability. We are happy to leave the past noise behind and take this company to its next stage, revenue wise but also valuation wise", concludes Bilski.
###
About NAGA
NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical Mastercard and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.
Language: |
English |
Company: |
The NAGA Group AG Hohe Bleichen 12 20354 Hamburg Germany |
E-mail: |
|
Internet: |
|
ISIN: |
DE000A161NR7 |
WKN: |
A161NR |
Indices: |
Scale 30 |
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005362/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom